FDG PET/CT. FDG-PET/CT Technical Committee Breakout 081204 Regular meetings of working groups with RSNA administrative support and milestones for delivery.

Slides:

Advertisements

Similar presentations

Edited version of presentation given at RSNA

Advertisements

Integrating the Healthcare Enterprise

What IHE Delivers 1 Radiation Exposure Monitoring: IHE REM Profile Kevin ODonnell Toshiba Medical Systems Co-chair, IHE Radiology Planning Cmte.

Integrating the Healthcare Enterprise

Change in longest diameter = -19%. Change in sum of perpendicular diameters = -21%

O Nearly all test-retest SUV measurements on the same scanner were within approximately 20% and 1.0 SUV units of each other. On different scanners SUV.

-- CTSA at RSNA 2010 PET/CT Analysis using 3D Slicer Jeffrey Yap PhD Ron Kikinis MD Wendy Plesniak PhD PET/CT Visualization and Analysis.

PET/CT Working Group Update Jayashree Kalpathy-Cramer Sandy Napel.

MEDIP - Platform independent software system for medical image processing IKTA4-6/2001 The aim of the project is to develop an informatical background.

Introduction to PET/CT in Oncology: Practical Aspects Jeffrey T. Yap, PhD Department of Imaging Dana-Farber Cancer Institute.

CALGB Fall Committee Meeting October 2006 Correlative Science Protocol Development Paula N. Friedman, PhD Director, Biospecimen & Correlative Science Operations.

Introduction to the State-Level Mitigation 20/20 TM Software for Management of State-Level Hazard Mitigation Planning and Programming A software program.

© 2013 The McGraw-Hill Companies, Inc. All rights reserved. Chapter 9 Tests, Procedures, and Codes.

National Public Health Performance Standards Local Assessment Instrument Essential Service: 1 Monitor Health Status to Identify Community Health Problems.

Imaging as a biomarker: standards for change measurements in therapy NIST, Gaithersburg, MD.

September, 2005What IHE Delivers IHE Eye Care Integration Profiles Andrew Casertano Department of Veterans Affairs.

AMERICAN COLLEGE OF RADIOLOGY March 23, OUR MISSION To foster the ongoing development of widely acceptable consistent imaging.

JumpStart the Regulatory Review: Applying the Right Tools at the Right Time to the Right Audience Lilliam Rosario, Ph.D. Director Office of Computational.

A small clinical trial has been designed between QIN site JHU, the U of Pittsburgh QIN, and the Adult Brain Tumor Consortium. In this trial, QIN methods.

FDG-PET/CT Technical Committee

-- CTSA at RSNA 2009 PET/CT Analysis using 3D Slicer Jeffrey Yap PhD Ron Kikinis MD Wendy Plesniak PhD Slicer3 Training Compendium.

FDG-PETCT Technical Committee Subcommittees Progress to Date (summary version) Software Version Tracking – Ling Shao Team: Ling Shao, Mike Casey, Steve.

DICOM and NM Taking the next step Jerold Wallis, MD.

Dan Spratt, MD Department of Radiation Oncology Neuroendocrine Prostate Cancer: FDG-PET and Targeted Molecular Imaging.

1 4D: Adaptive Radiotherapy & Tomotherapy Bhudatt Paliwal, PhD Professor Departments of Human Oncology & Medical Physics University of Wisconsin Madison.

PET in Colorectal Cancer. Indications for FDG PET Rising marker, (-) CT/MRI Nonspecific findings on CT/MRI, recurrence or post treatment changes? Known.

Integrating the Healthcare Enterprise Teaching File and Clinical Trial Export John Perry Fujifilm Medical Systems IHE Planning Committee.

Imaging as Biomarker for Prediction and Clinical Management: Need, Potential, and Issues for Multi-center Studies Daniel Sullivan, M.D. Duke University.

May 19-20, Quantitation, both single point and longitudinal*, of tumor metabolism via FDG-PET/CT that can be used practically and efficiently as.

Components of HIV/AIDS Case Surveillance: Case Report Forms and Sources.

Jeffrey Yap, PhD Ron Kikinis, MD Wendy Plesniak, PhD -1- CTSA at RSNA 2009 PET/CT Analysis using 3D Slicer Jeffrey Yap PhD Ron Kikinis MD Wendy Plesniak.

Reproducibility of Functional MRI – Progress Towards Profile Development Use Case: fMRI as a biomarker of functionally eloquent brain cortex for guiding.

The SNM Centralized IND & Clinical Trials Network Enabling Implementation Investigational & Approved PET Imaging in Multicenter Clinical Trials George.

Preparation NAME::ASMAA ALASY Supervision A::RASHA ATALLAH.

Scanner Validation via the SNM Clinical Trials Network Phantom Program Paul E. Christian Molecular Imaging Program Huntsman Cancer Institute University.

Moving Beyond Standard BMV Reports Using Data Repository Session 373 Presented by: Ian Proffer.

PET/CT Analysis using 3D Slicer Jeffrey Yap PhD Ron Kikinis MD Wendy Plesniak PhD Slicer3 Training Compendium.

Imaging as a biomarker: standards for change measurements in therapy NIST, Gaithersburg, MD.

Cancer Stem Cells: Some statistical issues  What you would like to do: Identify ways to design studies with increased statistical “power” in clinical.

The SNM Centralized IND & Clinical Trials Network Enabling Implementation Investigational & Approved PET Imaging in Large Multicenter Clinical Trials George.

PRINCIPLES AND APPROACHES 3D Medical Imaging. Introduction (I) – Purpose and Sources of Medical Imaging Purpose  Given a set of multidimensional images,

Integrating the Healthcare Enterprise Teaching File and Clinical Trial Export John Perry Fujifilm Medical Systems IHE Planning Committee.

FDG-PET/CT Technical Committee Purpose: to foster adoption of practical [I deleted cost-effective because I do not see us doing any cost-effective analyses.

TPS & Simulations within PARTNER D. Bertrand, D. Prieels Valencia, SPAIN 19 JUNE 2009.

Managing Radiation Dose: IHE REM Profile

Digital Reference Object Subcommittee Goals 1.Build a common reference DICOM test object (digital reference object or DRO) that can be generated by each.

Progress of the SNM Clinical Trials Network Michael Graham, PhD, MD Clinical Trials Network Co-Chair SNM President 1.

IHE Workshop – June 2006What IHE Delivers 1 Todd Kantchev, Siemens Molecular Imaging Jerold Wallis, Mallinckrodt Institute of Radiology Kevin O’Donnell,

IHE Workshop – June 2006What IHE Delivers 1 Todd Kantchev, Siemens Molecular Imaging Jerold Wallis, Mallinckrodt Institute of Radiology Kevin O’Donnell,

Diagnostic reference levels in Medical Imaging. Concept and practice

The PET/CT Working Group: CT Segmentation Challenge Informatics Issues Multi-site algorithm comparison Task: CT-based lung nodule segmentation.

Version 10. Mission; Foster adoption of… pragmatic and cost effective standards for accurate and reproducible longitudinal quantitation of biologic parameters.

Quantitative Imaging Biomarker Alliance PRINCIPAL LOGISTICAL AND FINANCIAL SUPPORT PROVIDED BY RSNA R EMARKS : W HAT DOES QIBA E XPECT OF QIBA-J APAN A.

Segmentation of 3D microPET Images of the Rat Brain by Hybrid GMM and KDE Tai-Been Chen Department of Medical Imaging and Radiological Science,

June 28-29, 2005IHE Interoperability Workshop 1 Integrating the Healthcare Enterprise Teaching File and Clinical Trial Export John Perry Fujifilm Medical.

Integrating the Healthcare Enterprise

Functional EHR Systems

Introduction to the QIBA Process and Metrology

Support- IRDiRC Proposed Work Plan And Communication Strategy

Multi-parametric Approach

Functional EHR Systems

Reporting Last modified: 8/2/11

FDG-PET/CT Technical Committee

Future of Thoracic PET Scanning

Digital Reference Object Subcommittee

Future of Thoracic PET Scanning

IQA 2018 QA Basics September 11, 2018 Day 1 Workshop 1.

FDG-PET/CT Technical Committee

Presentation transcript:

FDG PET/CT

FDG-PET/CT Technical Committee Breakout Regular meetings of working groups with RSNA administrative support and milestones for delivery during 2009 Regular “SNM cross-over” each TC tcon Communication of recommendations to vendors with reasonable expectation of implementation timeframe Expanded list of co-variates New Profiles QC Export standards (RIC, cross-check, Bresolin) De-identification irrespective of medium (DICOM cross-check) Trials and service apps (public & private label & access) Performance elements and standards (Yap)

Monitoring Rx Benefit = Individualized Medicine Convergence of Biomarkers and Diagnostics H/o Commercial Dx Individuals - thresholds Categorical, staging Workflow/# studies Binary – choice of Rx Biomarkers become Dx Population means, s Continuous, quantitative Automation/bias Longitudinal – monitor Rx Quantifying the effects of drugs in development may beg access to biomarkers as diagnostics

Quantitative Imaging Are we there yet?

Tumor Tracking Application Simplifying cancer patient management Compare, analyze, and track tumor progression with up to six sequential PET/CT studies SUV-based semi - automatic tumor segmentation Measurement of changes in tumor volume and metabolic activity Export tables and graphs or 3D contours

Reality Today with Siemens syngo TrueD Visualization 3 Time Points Display MIP Triangulation Gating Support Quantification 2D/3D Iso-Contouring 1-Click SUVmax RT Structure Export Trending Trending Charts VOI Propagation Deformable Registration Innovation is in our genes. 6 Siemens Medical Solutions Molecular Imaging Longitudinal Quantification in Hybrid Imaging

1.Automatic co-registration of multiple studies 2.Automatic segmentation of VOI based on % or SUV 3.CT or PET-guided lesion definition Timepoint 3Timepoint 2Timepoint 1

Compare tumors across any number of time points for multiple modalities Gradient-based PET segmentation for more accurate tumor volumes and statistics Export statistics for sharing with referring physicians Accurate registration allows the same region to be compared Difference images highlight variable tumor response Therapy Response Assessment

Automatically register serial studies for longitudinal accuracy Automatically segment and propagate ROIs for efficiency and robustness Quantify serial changes with a comprehensive set of metrics (SUV, Total Lesion Glycolysis, Functional Volume) and present in tabulated and graphical form Export tabulated data for easy utilization in 3 rd party analysis routines GE PET VCAR…Powerful Longitudinal Analysis

FDG-PET/CT Technical Committee Aim The aim of the QIBA FDG-PET/CT Technical Committee is to foster adoption of pragmatic and cost-effective standards for accurate and reproducible quantitation of tumor metabolism via longitudinal measures by FDG-PET/CT, with clinical relevance and known sigma.

System and protocol characterization SUV quantitation and ROI computation Covariates, data/version tracking, verification Digital referenc eobject Serial and multi-center SUV measurements SUV change analysis Profile claims Profile detail specification Precursor specifications Pattern for PET SUV Measurements as a Biomarker PET SUVs as a target- and mechanism-specific biomarker of response A.Drug development; Business decisions B.Drug development; Regulatory decisions C.Patient monitoring; Individualization of therapy Patient variability and effect size Uses:

FDG-PETCT Technical Committee Subcommittee Topics [chair] Quantitation Computation [David Clunie] Digital Reference Objects – Images [Paul Kinahan] Covariates rationale (Normalization) [Yuying Hwang] RoI Definition (and then Adoption) [Tim Turkington] Subcommittee slides deleted for sake of file size need updating to current status

Milestones Horizon/PET-CT Beyond RSNA’08 Quantitation Computation Documentation of terms RSNA ‘08 RSNA ‘09 RSNA ’10 and on Feasibility H, M, L Value H, M, L Priority H, M, L High Interoperability of Results Encoding Image Quality Metrics Calibration Phantoms Characterization Lo, Hi rads RoI Definition* Dynamic Range lesion size** High Medium High Quick Hits High *Adoption , Defined in 2008 **Ideal Phantom Current phantom by 2008

Quantitative Imaging Biomarker Alliance FDG- PET/CT Working Group Report RSNA News September 2008, Vol 18, No 9 Molecular Imaging and Biology (Print) (Online) Hallett WA, Maguire RP, McCarthy TJ, Schmidt ME, Young H. Considerations for generic oncology FDG-PET/CT protocol preparation in drug development. IDrugs, 2007 Nov; 10(11):791-6.

FDG PET/CT